 Long-term safety efficacy zidovudine patients advanced human immunodeficiency virus disease Zidovudine Epidemiology Study Group epidemiologic study long-term safety efficacy zidovudine patients advanced human immunodeficiency virus disease Data patients acquired immunodeficiency syndrome AIDS AIDS-related complex count /L Eighteen-month survival cohort Pretreatment factors increased survival time index diagnosis AIDS-related complex hematocrit count /L high functional status time diagnosis AIDS treatment days proportional hazards analysis development serious anemia significant factor early death zidovudine high proportion time chances survival anemia Serious leukopenia serious anemia patients Nonhematologic adverse events uncommon unreported adverse events